Media
CLINICAL TRIALS ARENA: ELI-002 2P was well-tolerated with no dose limiting toxicity or cytokine release syndrome across five cohorts.
O’Reilly EM, Wainberg ZA, Weekes CD, et al.
Presented at the American Society of Clinical Oncology Annual Meeting
June 2-6, 2023
Chicago, IL
PRECISION MEDICINE ONLINE: Elicio Therapeutics on Thursday said it closed a previously announced reverse merger with Angion
MARKETWATCH: Shares of Elicio Therapeutics were trading higher on the Nasdaq Friday, following the combination of the company with Angion Biomedica.
LABIOTECH: Elicio Therapeutics specializes in immunotherapeutic research in the field of cancer and infectious diseases. And its amphiphile technology (AMP) platform is the foundation for the various vaccine candidates in its pipeline, against cancer and other diseases.
PHARMA’S ALMANAC: I’ve seen two areas within oncology in particular that have grown significantly with revolutionary potential in the coming year: therapeutics targeting KRAS mutations and the re-emergence of cancer vaccines. Christopher Haqq, MD, PhD
MED CITY NEWS: Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes.
BUSINESS OF BIOTECH PODCAST: Chief Scientific Officer Peter DeMuth, PhD at Elicio HQ in Boston talks about how the platform works, and how it’s driving rapid clinical progress for the company’s robust pipeline of therapeutic vaccines in oncology.
Research Square, Dasari, et. al.
NPJ Vaccines – 2022
Seenappa LM, Jakubowski A, Steinbuck MP, et al.